Eris Lifesciences Limited
NSE: ERIS BSE: ERIS
NSE
1,382.90
-0.10 (-0.01%)
Prev Close
1383
Open Price
1379.2
Volume
81,150
Today Low / High
1357 / 1397.6
52 WK Low / High
815.85 / 1593.9
Range
1,314 - 1,452
BSE
1,383.10
1.40 (0.10%)
Prev Close
1381.7
Open Price
1380
Volume
1,046
Today Low / High
1354.1 / 1394.9
52 WK Low / High
815.5 / 1593
Range
1,314 - 1,452
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1382.9 (target range: 1,314 - 1,452), reflecting a change of -0.1 (-0.00723066%). On the BSE, it is listed at 1383.1 (target range: 1,314 - 1,452), showing a change of 1.4 (0.10132%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
21 Apr
1,379.20
0.27%
17 Apr
1,384.00
-0.07%
16 Apr
1,389.00
0.83%
15 Apr
1,429.00
-3.30%
11 Apr
1,359.05
1.89%
09 Apr
1,309.80
3.80%
08 Apr
1,283.35
2.91%
07 Apr
1,097.20
16.17%
04 Apr
1,360.00
-2.85%
03 Apr
1,383.15
-1.08%
02 Apr
1,390.00
-1.25%
01 Apr
1,400.00
-0.71%
28 Mar
1,405.00
0.88%
27 Mar
1,314.00
6.96%
26 Mar
1,356.00
-3.05%
25 Mar
1,366.90
-0.80%
24 Mar
1,405.00
-3.20%
Eris Lifesciences Limited Graph
Eris Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Eris Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,382.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,383.10 | 1,396.93 | 1,257.24 - 1,536.62 |
| 1,410.76 | 1,128.61 - 1,692.91 | ||
| 1,424.59 | 997.22 - 1,851.97 | ||
| Bearish Scenario | 1,383.10 | 1,369.27 | 1,232.34 - 1,506.20 |
| 1,355.44 | 1,084.35 - 1,626.53 | ||
| 1,341.61 | 939.12 - 1,744.09 |
Overview of Eris Lifesciences Limited
ISIN
INE406M01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
204,757
Market Cap
188,299,218,053
Last Dividend
14.7
Official Website
IPO Date
2017-06-30
DCF Diff
-1,807.85
DCF
3,192
Financial Ratios Every Investor Needs
Stock Dividend of ERIS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-13 | February 13, 25 | 7.35 | 7.35 | 2025-02-13 | 2025-03-09 | |
| 2022-08-11 | August 11, 22 | 7.35 | 7.35 | 2022-08-16 | 2022-09-04 | |
| 2021-08-05 | August 05, 21 | 6.01 | 6.01 | 2021-08-06 | 2021-08-28 | |
| 2020-08-13 | August 13, 20 | 5.5 | 5.5 | 2020-08-14 | 2020-09-03 | 2020-08-04 |
| 2020-03-19 | March 19, 20 | 2.87 | 2.87 | 2020-03-20 | 2020-04-10 | 2020-03-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,991.30 Cr | 996.68 Cr | 994.62 Cr | 0.4995 | 5.72 Cr | 71.48 Cr | 495.30 Cr | 391.98 Cr | 28.82 | 698.65 Cr | 0.1968 |
| 2023-03-31 | 1,661.82 Cr | 352.35 Cr | 1,309.47 Cr | 0.7880 | 6.10 Cr | 47.18 Cr | 421.66 Cr | 382.16 Cr | 28.10 | 548.08 Cr | 0.2300 |
| 2022-03-31 | 1,326.17 Cr | 260.81 Cr | 1,065.36 Cr | 0.8033 | 32.74 Cr | 50.41 Cr | 424.50 Cr | 406.11 Cr | 29.89 | 511.12 Cr | 0.3062 |
| 2021-03-31 | 1,192.64 Cr | 241.87 Cr | 950.78 Cr | 0.7972 | 5.09 Cr | 43.04 Cr | 387.61 Cr | 355.14 Cr | 26.16 | 439.46 Cr | 0.2978 |
| 2020-03-31 | 1,058.18 Cr | 178.74 Cr | 879.45 Cr | 0.8311 | 4.20 Cr | 35.29 Cr | 321.85 Cr | 296.50 Cr | 21.61 | 383.91 Cr | 0.2802 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 94.14 Cr | 7,048.84 Cr | 3,826.81 Cr | 2,586.1190 Cr | 2,781.27 Cr | 2,687.13 Cr | 189.03 Cr | 534.17 Cr | 20.93 Cr | 1.38 Cr | 15.73 Cr | 2,532.0770 Cr |
| 2023-03-31 | 56.02 Cr | 3,667.33 Cr | 1,446.65 Cr | 2,195.9880 Cr | 876.71 Cr | 820.69 Cr | 131.44 Cr | 377.38 Cr | 103.45 Cr | 8.74 Cr | 6.88 Cr | 443.2330 Cr |
| 2022-03-31 | 50.79 Cr | 2,272.14 Cr | 363.94 Cr | 1,908.3110 Cr | 84.41 Cr | 33.61 Cr | 117.91 Cr | 191.86 Cr | 62.62 Cr | 5.69 Cr | 420.84 Cr | 199.6460 Cr |
| 2021-03-31 | 36.87 Cr | 1,834.78 Cr | 258.36 Cr | 1,576.4210 Cr | 6.78 Cr | -30.09 Cr | 94.47 Cr | 77.88 Cr | 48.74 Cr | 6.11 Cr | 285.92 Cr | 166.9310 Cr |
| 2020-03-31 | 67.21 Cr | 1,552.31 Cr | 255.97 Cr | 1,296.3340 Cr | 12.14 Cr | -55.07 Cr | 69.48 Cr | 87.24 Cr | 42.43 Cr | 8.55 Cr | 3.20 Cr | 164.6900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 486.0050 Cr | -1,854.5220 Cr | 1,379.7790 Cr | 356.8430 Cr | 38.2230 Cr | 94.2450 Cr | -129.1630 Cr | 391.9830 Cr | 1,463.6990 Cr | 0.0000 Cr | -16.9400 Cr |
| 2023-03-31 | 291.7380 Cr | -982.1010 Cr | 688.0250 Cr | -549.6830 Cr | 5.1520 Cr | 56.0220 Cr | -841.4210 Cr | 404.6430 Cr | 817.8000 Cr | -99.9110 Cr | 4.7440 Cr |
| 2022-03-31 | 378.2640 Cr | -319.6100 Cr | -44.6990 Cr | 257.2310 Cr | 13.9550 Cr | 50.8700 Cr | -121.0330 Cr | 442.1980 Cr | 33.5000 Cr | -81.6230 Cr | -23.4450 Cr |
| 2021-03-31 | 375.3610 Cr | -323.3580 Cr | -82.3950 Cr | 349.5980 Cr | -30.3920 Cr | 36.9150 Cr | -25.7630 Cr | 394.4970 Cr | 0.0100 Cr | -74.6790 Cr | -24.9910 Cr |
| 2020-03-31 | 271.1100 Cr | 123.2880 Cr | -334.5910 Cr | 119.8280 Cr | 59.8070 Cr | 67.3070 Cr | -151.2820 Cr | 331.3500 Cr | -8.6020 Cr | -46.9790 Cr | 13.1780 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 722.12 Cr | 176.88 Cr | 545.24 Cr | 0.7551 | 169.11 Cr | 83.63 Cr | 6.15 | 254.53 Cr | 0.1158 |
| 2024-09-30 | 741.17 Cr | 392.38 Cr | 348.79 Cr | 0.4706 | 184.03 Cr | 91.59 Cr | 6.73 | 269.06 Cr | 0.1236 |
| 2024-06-30 | 719.72 Cr | 389.15 Cr | 330.57 Cr | 0.4593 | 174.05 Cr | 83.18 Cr | 6.11 | 251.63 Cr | 0.1156 |
| 2024-03-31 | 550.93 Cr | 274.56 Cr | 276.37 Cr | 0.5016 | 94.53 Cr | 70.96 Cr | 5.22 | 163.58 Cr | 0.1288 |
| 2023-12-31 | 483.48 Cr | 88.87 Cr | 394.61 Cr | 0.8162 | 133.99 Cr | 102.74 Cr | 7.55 | 179.71 Cr | 0.2125 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 150.02 Cr | 96.40 Cr | 246.42 Cr | 567.50 Cr | 256.28 Cr | 1,317.66 Cr | 520.44 Cr | 7,021.88 Cr | 3,844.73 Cr |
| 2024-06-30 | -1,400.63 Cr | 2,801.26 Cr | 1,400.63 Cr | 0.00 Cr | 0.00 Cr | 1,400.63 Cr | 0.00 Cr | 0.00 Cr | -3,222.03 Cr |
| 2024-03-31 | 1,400.63 Cr | 0.00 Cr | 1,400.63 Cr | 422.02 Cr | 189.03 Cr | 2,302.07 Cr | 523.65 Cr | 7,048.84 Cr | 3,826.81 Cr |
| 2023-12-31 | -190.62 Cr | 381.25 Cr | 190.62 Cr | 0.00 Cr | 0.00 Cr | 190.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 172.71 Cr | 19.52 Cr | 192.23 Cr | 349.75 Cr | 139.09 Cr | 961.15 Cr | 422.46 Cr | 3,875.19 Cr | 1,447.62 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 83.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 70.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 102.74 Cr | 91.43 Cr | 0.00 Cr | 0.00 Cr | 91.43 Cr | 264.15 Cr | 172.71 Cr | 0.00 Cr | 91.43 Cr |
| 2023-09-30 | 123.43 Cr | 84.19 Cr | 0.00 Cr | 0.00 Cr | 84.19 Cr | 172.71 Cr | 88.53 Cr | 0.00 Cr | 84.19 Cr |
| 2023-06-30 | 94.86 Cr | 81.79 Cr | 0.00 Cr | 0.00 Cr | 81.79 Cr | 137.81 Cr | 56.02 Cr | 0.00 Cr | 81.79 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Compliance Officer & Company Secretary
Mr. Milind Talegaonkar
Gender: male
Year Born:
Chairman & MD
Mr. Amit Indubhushan Bakshi
Gender: male
Year Born: 1975
Executive Director & Chief Operating Officer
Mr. Krishnakumar Vaidyanathan
Gender: male
Year Born: 1974
President of Sales & Marketing
Mr. Gagan Atreja
Gender: male
Year Born: 1968
Whole Time Director
Mr. Kaushal Kamlesh Shah
Gender: male
Year Born: 1979
Senior Vice President
Mr. Deepak Kapoor
Gender: male
Year Born: 1964
President Medical
Mr. Vijay S. Joshi
Gender: male
Year Born: 1953
Vice President
Mr. Manish Kapoor
Gender: male
Year Born: 1977
Chief Financial Officer
Mr. Sachin Shah
Gender: male
Year Born: 1980
Executive Director
Mr. Inderjeet Singh Negi
Gender: male
Year Born: 1971
FAQs about Eris Lifesciences Limited
Who is the CEO of the company?
The CEO is Mr. Amit Indubhushan Bakshi.
What is the current market price of the stock?
The current price is ₹1,382.90.
What is the 52-week price range?
The range is ₹815.85-1593.9.
What is the market capitalization of the company?
The market capitalization is ₹18,829.92 crores.
What is the dividend yield?
The dividend yield is 0.53%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 57.10.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Eris Lifesciences Limited (ISIN: INE406M01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹18,829.92 crores and an average daily volume of 204,757 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹14.7.